The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | The importance of detecting MRD in the treatment of AML
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, London, UK, describes the importance of detecting minimal residual disease (MRD) in acute myeloid leukemia, referencing a study performed by the late David Grimwade (PMID: 20805746). He notes that although there have been few studies performed on MRD, the MRD status in patients prior to receiving a transplant appears to be an important driver of relapse and he raises the possibility of using novel drugs immediately prior to transplantation in order to reduce the MRD status of these patients, thereby increasing their survival rates. Overall, it appears that MRD is likely to play a vital role in assessing novel drugs designed for patients who have developed evidence of MRD. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
